Cover Image
市場調查報告書

腦缺血:開發中產品分析

Brain Ischemia - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 245967
出版日期 內容資訊 英文 54 Pages
訂單完成後即時交付
價格
Back to Top
腦缺血:開發中產品分析 Brain Ischemia - Pipeline Review, H1 2017
出版日期: 2017年05月23日 內容資訊: 英文 54 Pages
簡介

腦缺血是腦部的血液供給受阻,造成腦部組織壞死及造成腦機能消失的腦中風。腦中風一般的原因是動脈粥狀硬化性心血管疾病。

本報告提供腦缺血的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

腦缺血概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

腦缺血:企業開發中的治療藥

腦缺血:大學/機關研究中的治療藥

腦缺血:開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品

腦缺血:企業開發中的產品

腦缺血:大學/機關研究中的產品

腦缺血的治療藥的開發企業

  • CohBar, Inc.
  • Lixte Biotechnology Holdings, Inc.
  • NeuroNascent, Inc.
  • NeurOp, Inc
  • Prolong Pharmaceuticals, LLC
  • Spectrum Pharmaceuticals, Inc.
  • Sylentis S.A.U.
  • Vect-Horus S.A.S.

腦缺血:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

腦缺血:最近的開發平台趨勢

腦缺血:暫停中的計劃

腦缺血:開發中止的產品

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9224IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Brain Ischemia - Pipeline Review, H1 2017, provides an overview of the Brain Ischemia (Central Nervous System) pipeline landscape.

Brain ischemia is a stroke is when the blood supply to any part of the brain is interrupted, resulting in tissue death and loss of brain function. The most common cause of stroke is atherosclerosis. Symptoms include loss of movement of body area, weakness, numbness, decreased vision, loss of memory, vertigo, loss of coordination and urinary incontinence. Treatment includes analgesics to control severe headache, anti-hypertensive medication to control high blood pressure and anti-platelet agents.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Brain Ischemia - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Brain Ischemia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Brain Ischemia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Brain Ischemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 10 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 7 molecules, respectively.

Brain Ischemia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Brain Ischemia (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Brain Ischemia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Brain Ischemia (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Brain Ischemia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Brain Ischemia (Central Nervous System)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Brain Ischemia (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Brain Ischemia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Brain Ischemia - Overview
    • Brain Ischemia - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Brain Ischemia - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Brain Ischemia - Companies Involved in Therapeutics Development
    • CohBar Inc
    • Lixte Biotechnology Holdings Inc
    • NeuroNascent Inc
    • NeurOp Inc
    • NoNO Inc
    • Prolong Pharmaceuticals LLC
    • Spectrum Pharmaceuticals Inc
    • Vect-Horus SAS
  • Brain Ischemia - Drug Profiles
    • 2-CCPA - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AB-002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ADA-409 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CIDEM-161 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CIGB-845 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drugs to Inhibit SRC-ND2 Interaction for Central Nervous System Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Humanin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LAU-0901 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LB-100 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NP-10679 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • phycocyanobilin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein to Activate GDNF for Brain Ischemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Sanguinate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Brain Ischemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize Gpr17 for Brain Ischemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize TRPM7 for Oncology, Ophthalmology, Cardiovascular and Central nervous System Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SPI-1620 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapy for Ischemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptide for Central Nervous System Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VHN-439 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Brain Ischemia - Dormant Projects
  • Brain Ischemia - Discontinued Products
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Brain Ischemia, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Brain Ischemia - Pipeline by CohBar Inc, H1 2017
  • Brain Ischemia - Pipeline by Lixte Biotechnology Holdings Inc, H1 2017
  • Brain Ischemia - Pipeline by NeuroNascent Inc, H1 2017
  • Brain Ischemia - Pipeline by NeurOp Inc, H1 2017
  • Brain Ischemia - Pipeline by NoNO Inc, H1 2017
  • Brain Ischemia - Pipeline by Prolong Pharmaceuticals LLC, H1 2017
  • Brain Ischemia - Pipeline by Spectrum Pharmaceuticals Inc, H1 2017
  • Brain Ischemia - Pipeline by Vect-Horus SAS, H1 2017
  • Brain Ischemia - Dormant Projects, H1 2017
  • Brain Ischemia - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Brain Ischemia, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top